Zealand Pharma Teams With Generate to Develop AI-Based Obesity Treatments

BloombergView source article

Part of story

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Danish obesity-drug developer Zealand Pharma partnered with US biotech company Generate Biomedicines to develop protein-based treatments for obesity and metabolic diseases using AI, in a deal valued at up to $1.2 billion.

Oct 13, 20262 sourcesObesity treatment AI applications

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Other sources for this story

Reuters

Zealand Pharma Teams With Generate to Develop AI-Based Obesity Treatments

Part of story

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Other sources for this story

Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion | Reuters

Zealand Pharma Teams With Generate to Develop AI-Based Obesity Treatments

Part of story

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Other sources for this story

Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion | Reuters